JP2016539925A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539925A5 JP2016539925A5 JP2016525584A JP2016525584A JP2016539925A5 JP 2016539925 A5 JP2016539925 A5 JP 2016539925A5 JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016525584 A JP2016525584 A JP 2016525584A JP 2016539925 A5 JP2016539925 A5 JP 2016539925A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- citrullinated
- disorder
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894042P | 2013-10-22 | 2013-10-22 | |
| US61/894,042 | 2013-10-22 | ||
| PCT/EP2014/072606 WO2015059168A1 (en) | 2013-10-22 | 2014-10-22 | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246722A Division JP2019048895A (ja) | 2013-10-22 | 2018-12-28 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539925A JP2016539925A (ja) | 2016-12-22 |
| JP2016539925A5 true JP2016539925A5 (enExample) | 2017-11-30 |
Family
ID=51866128
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Pending JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2018246722A Withdrawn JP2019048895A (ja) | 2013-10-22 | 2018-12-28 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018246722A Withdrawn JP2019048895A (ja) | 2013-10-22 | 2018-12-28 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9688769B2 (enExample) |
| EP (1) | EP3060250A1 (enExample) |
| JP (3) | JP2016539925A (enExample) |
| CN (1) | CN105899231A (enExample) |
| AU (2) | AU2014338991B2 (enExample) |
| CA (1) | CA2928317A1 (enExample) |
| WO (1) | WO2015059168A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6419064B2 (ja) * | 2012-03-29 | 2018-11-07 | ノビミューン エスアー | 抗ｔｌｒ４抗体およびその使用 |
| AU2014338991B2 (en) | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
| EP3332256A1 (en) * | 2015-08-06 | 2018-06-13 | NovImmune SA | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| JP6872024B2 (ja) * | 2016-10-04 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 合成分類指標の同定のためのシステムおよび方法 |
| JP7108638B2 (ja) * | 2017-02-07 | 2022-07-28 | ライフストーン・アーエス | 無菌性弛みによるインプラント関連のインプラント再置換リスクの診断のためのバイオマーカー |
| WO2020225549A1 (en) * | 2019-05-06 | 2020-11-12 | The Francis Crick Institute Limited | Method for preventing inflammation |
| CA3174429A1 (en) * | 2020-04-20 | 2021-10-28 | Edesa Biotech Research Inc. | Compositions and methods for treatment of acute respiratory distress syndrome |
| CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| ES2382039T3 (es) * | 2003-12-10 | 2012-06-04 | Novimmune Sa | Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos |
| EP1789067B8 (en) | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system |
| ES2348792T3 (es) * | 2004-12-10 | 2010-12-14 | Novimmune Sa | TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS. |
| AU2006284096B2 (en) | 2005-08-25 | 2012-03-29 | Avro Life Sciences, Inc. | Polymer conjugates of K-252a and derivatives thereof |
| SI1919979T1 (sl) * | 2005-08-25 | 2014-02-28 | Creabilis Therapeutics S.P.A. | Polimerni konjugati K-252A in njihovi derivati |
| US20070148704A1 (en) * | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| US7712333B2 (en) | 2006-03-29 | 2010-05-11 | Asahi Glass Company, Limited | Method for smoothing a surface of a glass substrate for a reflective mask blank used in EUV lithography |
| WO2009101479A2 (en) * | 2007-05-14 | 2009-08-20 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
| US8202650B2 (en) | 2007-07-24 | 2012-06-19 | Panasonic Corporation | Negative electrode material for nickel-metal hydride battery and treatment method thereof, and nickel-metal hydride battery |
| WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| US9140701B2 (en) * | 2009-08-18 | 2015-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis |
| HRP20251174T1 (hr) * | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| ES2721378T3 (es) * | 2011-01-10 | 2019-07-31 | Novimmune Sa | Anticuerpos anti-TLR4 y métodos de uso de los mismos |
| WO2013116590A1 (en) * | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| US20160159922A1 (en) | 2013-07-24 | 2016-06-09 | Vilara Ab | Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis |
| AU2014338991B2 (en) | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
-
2014
- 2014-10-22 AU AU2014338991A patent/AU2014338991B2/en not_active Ceased
- 2014-10-22 WO PCT/EP2014/072606 patent/WO2015059168A1/en not_active Ceased
- 2014-10-22 CA CA2928317A patent/CA2928317A1/en not_active Abandoned
- 2014-10-22 JP JP2016525584A patent/JP2016539925A/ja active Pending
- 2014-10-22 CN CN201480070143.8A patent/CN105899231A/zh active Pending
- 2014-10-22 US US14/520,904 patent/US9688769B2/en active Active
- 2014-10-22 EP EP14793805.4A patent/EP3060250A1/en not_active Withdrawn
-
2017
- 2017-06-26 US US15/632,882 patent/US10556960B2/en active Active
-
2018
- 2018-12-28 JP JP2018246722A patent/JP2019048895A/ja not_active Withdrawn
-
2020
- 2020-09-11 AU AU2020230333A patent/AU2020230333A1/en not_active Abandoned
- 2020-10-23 JP JP2020177986A patent/JP2021006592A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539925A5 (enExample) | ||
| Titcombe et al. | Pathogenic citrulline‐multispecific B cell receptor clades in rheumatoid arthritis | |
| JP2019048895A5 (enExample) | ||
| Vaisman-Mentesh et al. | Molecular landscape of anti-drug antibodies reveals the mechanism of the immune response following treatment with TNFα antagonists | |
| ES2989669T3 (es) | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana | |
| Rich et al. | Survey of the 2009 commercial optical biosensor literature | |
| Lindquist et al. | B cells and antibodies in Kawasaki disease | |
| JP2020536488A5 (enExample) | ||
| Zheng et al. | TCR repertoire and CDR3 motif analyses depict the role of αβ T cells in Ankylosing spondylitis | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| Goh et al. | A novel human anti-interleukin-1β neutralizing monoclonal antibody showing in vivo efficacy | |
| JP2015533788A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| HRP20201323T1 (hr) | Protutijela koja se specifično vežu na tl1a | |
| JP2012012402A5 (enExample) | ||
| JP2012143232A5 (enExample) | ||
| Von Büdingen et al. | Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands” | |
| Vergroesen et al. | N-glycosylation site analysis of citrullinated antigen-specific B-cell receptors indicates alternative selection pathways during autoreactive B-cell development | |
| Hoxha et al. | The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: a prospective multicentre study | |
| JP2014518883A5 (enExample) | ||
| JP2013531655A5 (enExample) | ||
| Pelzek et al. | Persistence of Disease‐Associated Anti–Citrullinated Protein Antibody–Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission | |
| JP2021500916A5 (enExample) | ||
| JP2018507254A5 (enExample) |